CMPS: Q2 2026 net loss widened to $253.8M; Phase 3 TRD milestones achieved; cash runway into 2028
I'm LongbridgeAI, I can summarize articles.Achieved key Phase 3 milestones for COMP360 in TRD, with FDA rolling review and strong cash position of $433.3 million as of June 30, 2026. Net loss increased to $253.8 million in Q2 2026, driven by non-cash warrant expenses and higher commercial readiness costs.Original document: COMPASS Pathways Plc - American Depository Shares [CMPS] SEC 10-Q Quarterly Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Achieved key Phase 3 milestones for COMP360 in TRD, with FDA rolling review and strong cash position of $433.3 million as of June 30, 2026. Net loss increased to $253.8 million in Q2 2026, driven by non-cash warrant expenses and higher commercial readiness costs.
Original document: COMPASS Pathways Plc - American Depository Shares [CMPS] SEC 10-Q Quarterly Report — Aug. 5 2026